May 15, 2017Platelets

Adenosine A2Areceptor agonists with potent antiplatelet activity

View Full Paper

Ask AI

Bookmark

Population

In vitro platelet models and adenosine A2A receptor models

Comparison

Adenosine A2A receptor agonists vs CGS21680 and NECA

Design

Preclinical

Authors

EFEduardo FuentesUniversity of Talca MFManuel Durán FuentesInstituto de Investigación Biomédica de Salamanca JCJulio CaballeroUniversity of Talca

Discussion

Member takes

Implication

PSB-15826 merits further preclinical development as antiplatelet agent; leaves open clinical translation of A2A agonists.

Structured PICO

Population

In vitro platelet models and adenosine A2A receptor models

Intervention

Adenosine A2A receptor agonists (PSB-15826, PSB-12404, and PSB-16301)

Comparator

CGS21680 and NECA

Outcome

Inhibition of platelet aggregation, platelet P-selectin cell-surface localization, and intraplatelet cAMP levelssurrogate

PSB-15826 is a potent adenosine A2A receptor agonist with strong antiplatelet activity, providing insights into the molecular requirements for this class of agents.

Cite This Study

Fuentes et al. (2017) studied this question.

synapsesocial.com/papers/6a73739c30bc69be694e5d98 https://doi.org/10.1080/09537104.2017.1306043

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Adenosine A2Areceptor agonists with potent antiplatelet activity

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Adenosine A2Areceptor agonists with potent antiplatelet activity

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider